Research on the Effectiveness of Neurorehabilitation After Stroke

Inclusion Criteria:

• Signed written informed consent.

• Age 18 to 80 years at the time of stroke onset.

• Early rehabilitation period (up to 6 months post-stroke).

• Diagnosis of acute cerebrovascular accident confirmed by MRI or CT.

• Upper limb paresis severity between 0 and 3 on the 6-point Medical Research Council (MRC) muscle strength scale.

• Ability and willingness to comply with the study protocol.

• Demonstrated motivation for rehabilitation.

Exclusion Criteria:

• Montreal Cognitive Assessment scale (MoCA) score less than 10 points.

• Hamilton Depression Rating Scale (Ham-D) score greater than 18 points.

• Modified Rankin Scale (mRS) score greater than 4 points.

• Pre-existing conditions that cause decreased muscle strength or increased muscletone in the upper limbs (e.g., cerebral palsy, traumatic brain injury) or rigidity (e.g., Parkinson's disease, contractures).

• Advanced arthritis or significant limitation of upper limb range of motion.

• Absence of part of the upper limb due to amputation for any reason.

• Any medical condition that may affect the conduct of the study or patient safety (e.g., mental illness).

• Alcohol abuse or recreational drug use within the 12 months preceding the study.

• Use of experimental medications or medical devices within the 30 days preceding thestudy.

• Inability to comply with research procedures, as determined by the researcher.

• The severity of the patient's condition, based on neurological or physical status,does not permit full rehabilitation.

• Visual acuity less than 0.2 in the weakest eye according to the Sivtsev visualacuity chart.

• Unstable angina and/or heart attack within the 30 days preceding the study.

• Recurrent stroke.

• Uncontrolled arterial hypertension.

• Ataxia.

• Presence of a pacemaker and/or other implanted electronic devices.

• Use of muscle relaxants.

• Peripheral neuropathy.

• Coexisting diseases in an exacerbation or decompensated stage requiring activetreatment.

• Allergic reactions or other skin lesions at the EEG electrode application sites atthe time of the study.

• Acute urinary tract infections.

• Acute thrombophlebitis.

• Any form of epilepsy.

• Benign and malignant neoplasms.